New Brunswick, N.J.-based J&J posted profits of $3.93 billion, or $1.44 per share, on sales of $20.35 billion for the three months ended Sept. 30, for a bottom-line gain of 4.5% on sales growth of 3.6% compared with Q3 2017.
Adjusted to exclude one-time items, earnings per share were $2.05, 2¢ ahead of Wall Street, where analysts expected sales of $20.05 billion.
“We are pleased with our strong third-quarter performance, which reflects continued above-market growth in our pharmaceutical business, accelerating sales momentum in our consumer business and consistent progress in our medical devices business,” chairman & CEO Alex Gorsky said in prepared remarks. “I’m confident that with our collaborative and inspired J&J colleagues around the world, unique broad-based business model and strategic investments in innovation, we are well positioned for success today and into the future.”
J&J said it now expects to post adjusted EPS of $8.13 to $8.18, up from $8.07 to $8.17 previously, on sales of $81.0 billion to $81.4 billion, compared with prior guidance of $80.5 billion to $81.3 billion.
JNJ shares were down a hair at $133.90 apiece today in pre-market trading.
Flat sales for medical device biz
Sales for J&J’s second-largest business, medical devices, were off -0.2% to $6.59 billion during the quarter, with international sales sliding -0.6% to $3.39 billion and domestic sales rising 0.3% to $3.20 billion.
The interventional solutions business paced the division with 18.1% growth to sales of $653 million. Vision sales were $1.13 billion, up 3.8%, followed by surgical revenues, which rose 1.3% to $2.38 billion.
Diabetes sales continued to show J&J’s wind-down of most of that business, sliding -22.2% to $315 million, and the orthopedics business was off by -4.2% at $2.11 billion compared with the same period last year.
On December 11-12,DeviceTalks West is taking over Orange County's medtech industry with one of the most anticipated conferences of the winter, bringing you the best and brightest minds in the industry.
Dr. Robert Greenberg, Executive Chairman, Alfred E. Mann Foundation
Gary Guthart, President and Chief Executive Officer, Intuitive Surgical
Reggie Groves, CEO, REVA Medical
Use code KEYNOTE to save an additional 10%.